Clinical Trial Detail

NCT ID NCT02611960
Title Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

nasopharynx carcinoma

Therapies

Pembrolizumab

Capecitabine + Docetaxel + Gemcitabine

Age Groups: adult

No variant requirements are available.